FDA-Cleared Automated Cell Counter for CSF Launched at AACC 2016
|
By LabMedica International staff writers Posted on 04 Aug 2016 |

Image: The GloCyte system delivers highly accurate and precise total nucleated cell and red blood cell counts using a novel combination of technologies (Photo courtesy of Advanced Instruments).
The system provides superior accuracy of low cell counts in cerebrospinal fluid samples. It is being introduced at the AACC Annual Scientific Meeting & Clinical Lab Expo (July 31 - August 4; Philadelphia, PA, USA). Linda Sandhaus, MD, University Hospitals Case Medical Center, presented a poster (#A-290) on August 2 titled GloCyte: A New Automated Technology for Cerebrospinal Fluid (CSF) Cell Counts.
Advanced Instruments, Inc. (Norwood, MA, USA) has received 510(k) clearance from the US Food & Drug Administration (FDA) to market its GloCyte Automated Cell Counter System and GloCyte Low and High Level Controls. The patented GloCyte System is intended to provide a quantitative determination of red blood cells (RBCs) and total nucleated cells (TNCs) in CSF collected from adult and pediatric patients. Currently, low cell counts often present a challenge to standard methods.
“To date, there has not been a way to provide dependable, low cell counts,” said John Coughlin, president and CEO, Advanced Instruments, “We use a novel combination of fluorescence, microscopy with digital image analysis principles, highly specific reagents, and an intelligent counting algorithm to provide accurate and precise cell counts. We are very excited as this marks a major achievement in giving laboratories a new way to obtain reliable and timely CSF results.”
Additional benefits of the GloCyte System are that the test requires only 30 microliters of sample per test, it uses disposable test cartridges ensuring no sample carryover and easy disposal, and it includes built-in quality control of Levey-Jennings charts and an audit table. The company expects to begin GloCyte shipments in September 2016.
Related Links:
Advanced Instruments
Advanced Instruments, Inc. (Norwood, MA, USA) has received 510(k) clearance from the US Food & Drug Administration (FDA) to market its GloCyte Automated Cell Counter System and GloCyte Low and High Level Controls. The patented GloCyte System is intended to provide a quantitative determination of red blood cells (RBCs) and total nucleated cells (TNCs) in CSF collected from adult and pediatric patients. Currently, low cell counts often present a challenge to standard methods.
“To date, there has not been a way to provide dependable, low cell counts,” said John Coughlin, president and CEO, Advanced Instruments, “We use a novel combination of fluorescence, microscopy with digital image analysis principles, highly specific reagents, and an intelligent counting algorithm to provide accurate and precise cell counts. We are very excited as this marks a major achievement in giving laboratories a new way to obtain reliable and timely CSF results.”
Additional benefits of the GloCyte System are that the test requires only 30 microliters of sample per test, it uses disposable test cartridges ensuring no sample carryover and easy disposal, and it includes built-in quality control of Levey-Jennings charts and an audit table. The company expects to begin GloCyte shipments in September 2016.
Related Links:
Advanced Instruments
Latest AACC 2016 News
- Molecular Test Detects Three Arboviruses in Plasma Samples
- Derived Exosomal Protein Biomarkers in Alzheimer’s Disease Diagnosis
- New Biochip Array Developed for ApoE4 Classification
- Cell-Free DNA Identifies Liver Transplant Patients with Acute Rejection
- New Method Tested for Early Diagnosis Pediatric Diabetic Nephropathy
- Semen Analysis Portfolio with Two New Products Featured at AACC 2016
- Automation Solutions for Clinical Diagnostic Equipment Showcased at AACC 2016
- New Tubes Designed for Medium Sample Volumes
- Multi Sample Osmometer Improves Testing Efficiency
- Innovative Information System Optimizes Laboratory Processes
- Innovative eLearning Interface Seamlessly Connects Competency Data
- Cloud-Based Connectivity Platform Advances Decentralized Healthcare
- Adhesives Research to Present Hydrophilic Adhesive Technologies
- Point-of-Care Immunoassay Analyzer on Display at AACC Annual Meeting
- Assay for Determination of 17-OH Progesterone to Be Featured at AACC Annual Meeting
- Fully Automated HbA1c Analyzer Available for Inspection at AACC Annual Meeting
Channels
Clinical Chemistry
view channel
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreFDA Authorization Adds Gabapentin Testing to Roche Mass Spectrometry Solution
Clinical laboratories use mass spectrometry for applications requiring highly sensitive and specific measurement, including steroid hormone measurement, vitamin D testing, and therapeutic drug monitoring.... Read moreMolecular Diagnostics
view channel
Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis
Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more
Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk
Breast cancer screening can reduce mortality, but early detection remains challenging when tumors are small or difficult to identify through imaging. Blood-based liquid biopsies offer a potential complementary... Read more
Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes
Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories.... Read moreHematology
view channel
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read more
Study Confirms Blood Products Remain Viable After Three Weeks in the Arctic
Trauma and hemorrhage care in Canada’s High Arctic is complicated by long evacuation times, extreme temperatures, and limited access to blood products. In remote military and northern communities, reaching... Read moreImmunology
view channel
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
Complete Malaria Genomes Could Improve Species Identification and Surveillance
Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more
Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum
Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more
Automated Microbial Identification and Susceptibility System Gains FDA Clearance
Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more
Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
Gastrointestinal infections can be caused by bacterial, viral, or parasitic pathogens, making targeted test selection important for clinical laboratories. Fixed syndromic panels may be broader than necessary... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more








